Joined November 2010
- Tweets 2,591
- Following 1,965
- Followers 2,412
- Likes 10,346
48 Photos and videos
Pinned Tweet
3 Aug 2023
How I know it's still early days for biology:
4
10
70
13,611
Nish retweeted
Small molecules to correct disease. Listen to @srikosuri of @OctantBio on The Long Run. Sponsors: @AlphaSenseInc and Dash Bio. timmermanreport.com/2026/06/…
1
3
10
1,468
Jun 10
Always true
2
206
Nish retweeted
I'm pretty excited about AI in Biology.
I bet my research career on it. And now I'm betting my investment career on it!
But somehow, spending this past week at CSHL's 90th symposium—which was exclusively dedicated to this topic this year—made me even more bullish!
One of the most electric conferences I've been to in a while... maybe ever. Back-to-back talks from the top scientists and industry leaders in this field. Even though my job is to cover this domain, it was a visceral reminder of how quickly things are moving.
Fantastic job curating and organizing by @pkoo562 and @TonyZador.
My plan is to get some notes up on what I saw in the next week or two on CoB! 🧬
4
16
200
13,747
Nish retweeted
May 29
We're so used to reagents being unreliable in biology that many people probably bought these antibodies, spent weeks troubleshooting them, and then marked them as "bad" without reporting back to Thermo... We just accept that you have to sift through multiple antibodies every time you design a new assay
Catalogue entries for more than 100 antibodies sold by the research services and supply company Thermo Fisher Scientific contain images that have apparently been manipulated, according to a pair of science sleuths.
go.nature.com/4wZqGEE
6
29
192
23,921
Nish retweeted
May 29
Claude Opus 4.8 dropped yesterday, so we ran it through RefusalBench, our new benchmark measuring how LLMs handle biosecurity risk.
We found that 4.8 got meaningfully better at distinguishing safe biological prompts from dangerous ones.
In our previous analysis, Opus 4.7 refused 77% of legitimate protein-design prompts; in Opus 4.8, that number drops to 57%. While both versions still refuse 100% of clearly-dangerous prompts.
4.8 still over-refuses more than Opus 4.5/4.6 did (both refuse ~33% of benign prompts). So this is a recovery, not a full return to the earlier calibration.
Leaderboard, data and preprint below ↓
4
6
22
3,007
Nish retweeted
May 28
Protuoso Biosciences is officially launched from stealth with a $9.5 million seed financing!
Read the full announcement here: businesswire.com/news/home/2…
1
284
Nish retweeted
Today we're launching Deliverome Bio, a focused research organization tackling one of the biggest bottlenecks in medicine: getting therapeutics to tissues beyond the liver.
3
6
42
18,990
May 22
When reviewing a pitch deck I almost always ignore the TAM slide
May 22
Google was not constrained by the online advertising marketsize when it launched. Uber was not constrained by the taxicab marketsize when it launched. Doordash was not constrained by the food delivery marketsize when it launched.
But many journalists and financial analysts are still constrained by their inability to see a future that is different from today.
6
874
Nish retweeted
May 12
I’ve always believed the No.1 application of AI should be to improve human health.
That work started with AlphaFold, and now at @IsomorphicLabs with the mission to reimagine drug discovery and one day solve all disease!
We are turbocharging that goal with $2.1B in new funding.
731
2,645
21,264
3,153,705
May 12
big congrats to the Isomorphic team! rooting for them and excited to see what comes of this
May 12
Today marks a pivotal moment for Isomorphic Labs. We have secured $2.1 Billion in our second external funding round, led by Thrive Capital. They are joined at the table by Alphabet, GV and new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund.
This milestone accelerates our ability to build the pioneering novel AI models that power our AI drug design engine (IsoDDE) and deploy them at scale: delivering scientific breakthroughs with a precision previously thought impossible, accelerating and expanding our pipeline of therapeutic programs toward the clinic. All with the ultimate goal of delivering life-changing new medicines to patients.
Moving forward, we will scale our drug candidate pipelines across multiple therapeutic areas, expand our global footprint, and push the boundaries of frontier AI research to power our drug design engine.
Deeply grateful to everyone sharing our vision to solve all disease with AI. Let’s build the future of medicine.
Read the full announcement here: bit.ly/4v2OI03
1
4
796
Nish retweeted
May 12
This is so cool!
May 12
Today we're publishing our index of unmet needs in human disease: 2443 indications scored and ranked on burden of disease, prevalence, pipeline activity, and treatment burden. We hope this will help drug developers identify overlooked medical problems
convoke.bio/blog/introducing…
14
95
30,375
May 12
1, except I don't think it's 'one of'
Biology is one of the most interesting domains where I'm seeing AI being applied. @Convokebio is hosting a small event with lightning talks to introduce the space to a technical audience without a bio background. There's a few spots left, DM me if you'd like to be added.
1
17
2,373
May 10
(un)fortunately, this is very true
People at major AI labs (using internal models) 3-4 months ahead of startup silicon valley engineers
SV founders/eng 3-6 months ahead of NY
NY founders/eng 6-12 months ahead of rest of world
Most people have no idea how fast AI shifting as 1-2 years behind SOTA
"The future is here, just not equally distributed" - Robert Heinlein
338
Nish retweeted
May 9
Fun interactive science app ideas | Part 3
Played around with generating 3D biological structures and made an app to explore them interactively
UI Design
GPT Images 2
Code
Gemini 3.1 Pro
More demos ↓
526
2,142
17,145
2,261,088
Nish retweeted
Yes, we have full CTDs here, completely with correspondence from FDA:
ctdcommons.org/
Working with 1DS to get more funding for this and so on so we can better operationalize
3
8
76
9,963
Nish retweeted
I'll leave the hantavirus risk discussion to the experts, but it's a little surprising to me that the full sequence hasn't been published yet - so far ID has been PCR only. Africa CDC has an amazing genomic surveillance capability so I'd expect we'll see one soon
6
36
5,253
May 2
👀
May 1
More details from the cursor life sciences GM here: linkedin.com/posts/philkjohn…
1
788
Apr 30
A very annoying side effect of this is that meeting note summary apps will randomly and silently fail to summarize notes from legit biology discussions
Apr 26
I would do the bioinformatics myself at this point but I've already forgotten how
3
4
62
46,041